Work

CUPID ( 64 Cu-TLX592 phase I PK, biodistribution and dosimetry): A proof-of-concept study of TLX592-targeted alpha therapy in prostate cancer.

Year: 2025

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2025.43.5_suppl.177

Authors: Nat Lenzo, Anne Capp, Aviral Singh, Giuseppe Cardaci, Neel Patel, Michael Wheatcroft, David Cade

Institutions: GenesisCare, Telix Pharmaceuticals Limited (Australia)

Language: English

Topic: Radiopharmaceutical Chemistry and Applications

Subfield: Radiology, Nuclear Medicine and Imaging

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W4407699239

Cites:

Cited by:

Related to: 10